ClinicalTrials.gg

Program

608

Also written as “608 Q2W”, “608 Q4W” and “608 dose”.

Its studies are mostly in Psoriasis · Non-Radiographic Axial Spondyloarthritis · Spondylitis, Ankylosing, led by 3SBio.

Furthest: phase 3, since Sep 8, 20227 company-led studies, 5 open or runningNext primary completion: Jan 14, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
3SBio75 open or runningphase 3since Sep 8, 2022Apr 25, 2020Jan 14, 2027phase 3 · NCT07261644

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 25, 2020First study: phase 1 study in Moderate to Severe Plaque PsoriasisFirst studyNCT04367441 · 62 enrolled · China
  2. Sep 8, 2022Phase 3 study in PsoriasisNCT05536726 · 458 enrolled · China
  3. Jan 10, 20242 phase 2 studiesNCT06222671, NCT06242652
  4. Feb 28, 2024Phase 3 study in Plaque Psoriasis PatientsNCT06299982 · 750 planned
  5. Nov 21, 2025Phase 3 study in Spondylitis, AnkylosingNCT07261644 · 500 planned · China
  6. Jan 9, 2026Phase 3 study in Non-Radiographic Axial SpondyloarthritisNCT07349329 · 380 planned · China

Ahead

  1. Jan 14, 2027Primary completion: phase 3 study in Spondylitis, AnkylosingNCT07261644
  2. Apr 19, 2028Primary completion: phase 3 study in Non-Radiographic Axial SpondyloarthritisNCT07349329

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07349329Non-Radiographic Axial Spondyloarthritis · China3Not yet recruitingApr 19, 2028380
NCT07261644Spondylitis, Ankylosing · China3RecruitingJan 14, 2027500
NCT06299982Plaque Psoriasis Patients3Not yet recruitingJan 30, 2025750
NCT06242652Spondylitis, Ankylosing · China2Active, not recruitingFeb 27, 2025250
NCT06222671Axial Spondyloarthritis · China2RecruitingSep 22, 2025180
NCT05536726Psoriasis · China3CompletedOct 20, 2023458
NCT04367441Moderate to Severe Plaque Psoriasis · China1UNKNOWNOct 31, 202062

How it is read

Names in the registry

  • “608”, 4 entries
  • “608 Q2W”, 2 entries
  • “608 Q4W”, 2 entries
  • “608 dose”, 1 entry
  • “608 Dose A”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.